Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October
Previous Archive
19 April 2024 | Story André Damons | Photo Stephen Collett
Prof Salim Karim
Prof Francis Petersen, Vice-Chancellor and Principal of the University of the Free State (left) and Prof Gert Van Zyl, Faculty of Health Sciences Dean (right) conferred Prof Salim S Abdool Karim honorary doctorate for his ground-breaking research in AIDS and COVID-19. He received the degree PhD in Medical Virology (h.c.) during the Faculty of Health Sciences graduation ceremony.

With the case study of Caprise 256, a young woman in his AIDS study, and her potent antibody that kills HIV, Prof Salim S Abdool Karim, honorary doctorate recipient, conveyed the message of the power of science, knowledge and discovery to motivate the graduates from the Faculties of Health Sciences and Theology and Religion at the University of the Free State (UFS).

Prof Karim, renowned for his ground-breaking research in AIDS and COVID-19, received the degree PhD in Medical Virology (h.c.) during Thursday’s (18 April 2024) graduation ceremony.

From humble beginnings

“It is great honour and privilege to be here and accept this honorary doctorate. I first went to university in 1978 and wanted to study engineering but did not have the money to pay for registration as I come from a poor background. So, I attended classes anywhere. But then I was accepted to study medicine at the University of Natal with a full scholarship and that was the end of my career in engineering.

“From that humble beginning to today where you might have watched me on TV trying to share with you what we know about COVID-19 and other infectious diseases, is a great culmination of a career and I am deeply honoured and privileged to receive this honorary doctorate”, he said shortly after accepting his fifth honorary degree.

Prof Abdool Karim, a clinical infectious disease epidemiologist who is widely recognised for scientific contributions to AIDS and COVID-19, also shared with graduates the last 20 years of his academic journey with an example to illustrate how exciting the acquisition of knowledge and thrill of discovery can be. He talked about his work with AIDS and says it remains one of the world’s greatest challenges. Last year, he said, there were 1.3 million new infections and over 700 000 deaths as a result of AIDS.

Caprisa 256’s antibody

“I have devoted almost 40 years of research to looking for solutions for the AIDS problem and one of the biggest problems we are dealing with is the high rate of HIV, particularly in young girls. In 2003 we started a study to begin to understand why young women are at such a high risk of HIV.

“We enrolled hundreds of young women without HIV. We provided them with all kinds of knowledge to try and keep them HIV-free. Amongst those women we enrolled was participant 256, a young lady and she acquired HIV infection two years later in 2005.”

It would later turn out that this young woman, codename Caprisa 256, has a very special antibody – the kind that can kill a wide range of HIV – which is referred to as a broadly neutralising antibody. It is an antibody researchers tried to ellicit in making vaccine.

It turned out that not only is her antibody able to kill a wide range of HIV, it is a highly potent antibody. After testing and cloning a cell in the blood and growing it in a culture and harvesting the antibody, it was genetically manipulated to get a better antibody.

The Director of the Centre for the AIDS Programme of Research in South Africa (Caprisa), explained that it took two-and-a-half years to manufacture this antibody in the US and the first South African was injected with it in 2020. They enrolled over 1 000 women in a study with half of the women receiving the placebo and half the antibody. The question whether it works, or protects humans from the HIV will only be answered next year, Prof Abdool Karim explained. 

The 3 Ps

“What I am trying to convey to you, it’s the power of science, the power of knowledge, the power of discovery and when each of you goes out into the world, I want to leave you with the message that there are three valuable lessons that I have learned in this 20-year journey of Caprisa 256.

“The first one is find your passion, find something that excites you when you wake up in the morning. There will be people that would want to pull you down, you will have to stand firm. You have to show that you are passionate and committed and regardless of the obstacles, you will persevere. Find your passion and persevere. And as you do that, always remember the pursuit of excellence. I know that each of you will bring to this world your own humanity, your own values, and we are in this world, in a situation where we are in desperate need of people who will bring their humanity and their wisdom to bear.”

Prof Francis Petersen, Vice-Chancellor and Principal of the UFS, congratulated Prof Abdool Karim on his honorary degree and praised his groundbreaking research on Aids and COVID-19, as well as his exceptional work in medical virology over the years. “Prof Abdool Karim led the South African response to COVID-19, providing us as the public, as well as the government with scientific advice on the virus, new variants, and flattening the curve. Prof Abdool Karim has the ability to easily explain complex science to members of the general public in such a way that they are able to understand it. He played a critical role during the pandemic, and for this as well as for his research on Aids, South Africa is indebted to him.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept